Clinical Trial Update: Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G) [EARLY_Phase 1]

View source ↗

Summary

The APATIT-G early phase 1 trial evaluating avatrombopag for temozolomide-induced thrombocytopenia in glioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Avatrombopag (avatrombopag)

Snippet

Sponsor: University of Rochester | Conditions: Thrombocytopenia | EARLY_Phase 1 | Status: WITHDRAWN